A rAised blood level of low-density-lipoprotein cholesterol (LDL-C) and type 2 diabetes mellitus (T2DM) are two conventional risk factors for cardiovascular disease (CVD) [1] [2] [3] . A strictly managed level of LDL-C in patients with T2DM is recommended in practical guidelines [4] [5] [6] . In spite of the prevalent use of statin, which is an inhibitor of cholesterol synthesis, the control of LDL-C levels in patients with T2DM is considered to be insufficient [7] ; therefore, other strategies for the regulation of lipid metabolism in patients with T2DM are required.
by inhibiting the Niemann-Pick-like 1 enterocyte receptor, thereby reducing blood LDL-C levels [8] [9] [10] [11] . Recently, ezetimibe has been used not only as a monotherapeutic agent, which is a common treatment strategy in Japan, but also as an adjunct to statin therapy [11] . Despite several reports on ezetimibe treatment in T2DM patients [12] [13] [14] , there are very few clinical reports that have compared the effects of ezetimibe on lipid parameters between patients with and without T2DM [14] . Furthermore, it is still unclear whether the change of cholesterol synthesis/absorption by ezetimibe is associated with the reduction of plasma lipid parameters. The present study therefore aimed to compare the effects of ezetimibe on lipid parameters between hypercholesterolemic patients with and without T2DM, by examining levels of LDL-C, non-HDL-C, and cholesterol synthesis-and absorption-related markers.
A two-way ANOVA was used to compare the changes in respective parameters between the groups with adjustments for substantial confounding factors such as age, gender, smoking, and BMI. Statistical significance was set at a P-value of < 0.05. All the analyses were performed using the Dr. SPSS II software package (SPSS, Inc., Chicago, IL, USA).
results
Among the measured baseline characteristics, TC, LDL-C, non-HDL-C, Apo-B, and Apo-E in hypercholesterolemic patients with T2DM were significantly lower than in the patients without T2DM. Compared with the non-T2DM group, the T2DM group had significantly higher hs-CRP, glucose, and HbA1c levels (Table 1) . Patients undergoing ezetimibe monotherapy or combined statin therapy were present in identical proportions in the two groups. In the T2DM group, 32 and 10 patients received ezetimibe monotherapy and combined statin therapy, and 16 and 5 patients received ezetimibe monotherapy and combined statin therapy, respectively, in the non-T2DM group. Following the 12-week ezetimibe treatment, the levels of TC, LDL-C, non-HDL-C, Apo-B, and Apo-B/ A I were significantly reduced in both groups (Table  1) . However, ezetimibe resulted in greater reductions in both LDL-C and non-HDL-C in the T2DM group than in the non-T2DM group (LDL-C: -25.1% in T2DM group versus -20.5% in non-T2DM group, non-HDL-C: -20.5% in T2DM group versus -17.4% in non-T2DM group) (Fig. 1 ). These differences reached statistical significance after adjusting for the confounding factors of age, gender, smoking, and BMI. Although hs-CRP was significantly increased at baseline in the T2DM group compared with that in the non-T2DM group, ezetimibe effectively reduced it in the T2DM group. Finally, hs-CRP did not differ between the two groups twelve weeks after ezetimibe treatment.
In a similar analysis for the subgroups undergoing ezetimibe monotherapy that was adjusted for age, gender, smoking, and BMI, the T2DM group also exhibited significantly greater reductions in LDL-C and non-HDL-C from baseline (-23.7 and -20.4%, respectively) than those of the non-T2DM group (-19.6 and -17.5%, respectively). Additionally, the subgroup with T2DM having hypertriglycemia ( ≥ 150 mg/dL) (n = 16) displayed similar reductional levels of LDL-C and non-
subjects and Methods
Hypercholesterolemic patients with T2DM (T2DM group) (n = 42; men/women = 24/18; mean age = 65.8 ± 7.8 years) and without T2DM (non-T2DM group) (n = 21; men/women = 7/14; mean age = 62.5 ± 8.2 years) were enrolled in the study. Ezetimibe (10 mg/ daily) was prescribed according to LDL-C levels as recommended by the revised guidelines of the Japan Atherosclerosis Society (JAS) [4] . During the 12 weeks of ezetimibe treatment, the patients' usual drugs and nutritional therapies (maintained for the previous 12 weeks) were left unchanged. (If altered, the patient would have been considered a dropout case; however, there were no dropout cases in the present study.) The study protocol was approved by the internal review board of Utsunomiya Social Insurance Hospital and all patients gave informed consent.
At baseline and after 12 weeks of treatment, the body mass index (BMI) and systolic/diastolic blood pressure of each patient were measured. Blood samples were also collected between 8:00 and 10:00 AM after overnight fasting and the following parameters were measured for all patients: glucose, hemoglobin A1c (HbA1c), total cholesterol (TC), triglyceride (TG), high-density-lipoprotein cholesterol (HDL-C), non-HDL-C (calculated by subtracting HDL-C from TC), apolipoprotein A I (Apo-A I), apolipoprotein B (Apo-B), apolipoprotein E (Apo-E), Apo-B: Apo-A I ratio (Apo-B/A I), remnant-like particle cholesterol (RLP-C), and high-sensitivity C-reactive protein (hs-CRP). Cholesterol synthesis-related (lathosterol) and absorption-related (cholestanol, campesterol, and sitosterol) markers were measured in many, not all, of the patients (n=26 in T2DM group, n=13 in non-T2DM group). LDL-C was calculated by the Friedewald equation because all patients had TG levels < 400 mg/ dL [15] . Serum RLP-C was measured by an immunoseparation method (Jimro; Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan) as previously described [16] . The hs-CRP was measured using an ultra-high-sensitivity latex turbidimetric immunoassay (Behring Nephelometry, Tokyo, Japan). Cholesterol synthesis/ absorption-related markers were determined by gasliquid chromatography [17] .
Unpaired t-tests and chi-square tests were used to compare the above parameters between the two groups. Paired t-tests were used to examine the changes in respective parameters within each group. iary cholesterol [18] , inconsistent data have also been reported [19, 20] . Because baseline LDL-C and non-HDL-C were already significantly lower in the present study, this may account for the lower levels of markers for cholesterol absorption at baseline than expected in the T2DM group. Twelve weeks after ezetimibe treatment, sitosterol and campesterol were significantly reduced in both groups when compared with baseline levels. Furthermore, significant reduction of cholestanol by ezetimibe was observed in the T2DM group, but not in the non-T2DM group. The changes of these cholesterol absorption markers from the baseline were positively associated with reduced LDL-C and non-HDL-C levels in the T2DM group. Therefore, it is tempting to speculate that pronounced effects of ezetimibe on the prevention of cholesterol absorption lead to the effective reduction of LDL-C and non-HDL-C in T2DM. In contrast to the previous reports in which ezetimibe monotherapy was stated to reduce LDL-C levels more in individuals with hypertriglyceridemia [21] , the lowering effects on LDL-C and non-HDL-C by ezetimibe were equal in the subgroups with T2DM irrespective of the presence of hypertriglyceridemia. Non-HDL-C, which represents a measure of cholesterol in Apo-B-containing lipoproteins, including LDL, very low-density lipoprotein, and remnant intermediate-density lipoprotein, is considered as a better predictor of CVD risk than LDL-C, particularly in hypertriglyceridemic patients [5, 22] . As there are few reports that have focused on the association between HDL-C (-24.4 and 21.8%, respectively) compared to that without hypertriglycemia (<TG 150 mg/dL) (n = 26; -24.6 and 19.8%, respectively).
At baseline, the levels of lathosterol, campesterol, sitosterol, and cholestanol did not differ between the two groups ( Table 1) . Although the levels of both campesterol and sitosterol decreased after the 12-week ezetimibe treatment in both groups, ezetimibe did not influence the level of lathosterol, a marker for cholesterol synthesis, in either group. Interestingly, ezetimibe significantly reduced cholestanol levels in the T2DM group, but not in the non-T2DM group, and the reduction of cholestanol was significantly correlated with those of LDL-C and non-HDL-C in the T2DM group (Table 2) . Furthermore, the reductions of other markers for cholesterol absorption, sitosterol and campesterol, were also positively associated with that of LDL-C or non-HDL-C in the T2DM group.
discussion
In the present study, the T2DM group had lower LDL-C and non-HDL-C levels at baseline than the non-T2DM group. Nonetheless, ezetimibe reduced the levels of both LDL-C and non-HDL-C in the T2DM group more than those in the non-T2DM group. The markers for cholesterol synthesis/absorption, lathosterol, campesterol, sitosterol, and cholestanol, at baseline did not differ between the T2DM group and the non-T2DM group. Although T2DM is shown to be associated with higher absorption of dietary and bil- terol-lowering approach using ezetimibe for T2DM patients. This study has a limitation related to the interpretation of data that warrants mention. The sample size of the two groups may be too small to produce definite conclusions. Therefore, studies with larger numbers of patients are required to confirm the effects of ezetimibe on the lipid parameters reported here.
In summary, the present study suggests that ezetimibe can reduce the levels of LDL-C and non-HDL-C to a greater extent in hypercholesterolemic patients with T2DM than in those without T2DM, in addition to lowering absorption-related markers.
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ezetimibe and non-HDL-C, the results presented here provide valuable information regarding the potential efficacy of ezetimibe on reducing serum levels of non-HDL-C in hypercholesterolemic patients with T2DM. Of interest, we also found that cholestanol, a metabolite of cholesterol, showed a significant reduction within the T2DM group after ezetimibe treatment; this was associated with the decrease of LDL-C and non-HDL-C. Cholestanol represents the 5α-saturated derivative of cholesterol and reflects intestinal cholesterol uptake [23] . Serum plant sterol (campesterol, sitosterol) levels reflect their dietary amount, whereas the serum cholestanol content is derived not only from diet but also from bile. Importantly, cholestanol is clinically reported to be a marker for increased allcause and CVD mortality [24, 25, 26] . Therefore, our present data might give a unique insight into a choles-
